Abstract

While oxidative stress has been linked to multiple sclerosis (MS), the role of superoxide-producing phagocyte NADPH oxidase (Nox2) in central nervous system (CNS) pathogenesis remains unclear. This study investigates the impact of Nox2 gene ablation on pro- and anti-inflammatory cytokine and chemokine production in a mouse experimental autoimmune encephalomyelitis (EAE) model. Nox2 deficiency attenuates EAE-induced neural damage and reduces disease severity, pathogenic immune cells infiltration, demyelination, and oxidative stress in the CNS. The number of autoreactive T cells, myeloid cells, and activated microglia, as well as the production of cytokines and chemokines, including GM-CSF, IFNγ, TNFα, IL-6, IL-10, IL-17A, CCL2, CCL5, and CXCL10, were much lower in the Nox2−/− CNS tissues but remained unaltered in the peripheral lymphoid organs. RNA-seq profiling of microglial transcriptome identified a panel of Nox2 dependent proinflammatory genes: Pf4, Tnfrsf9, Tnfsf12, Tnfsf13, Ccl7, Cxcl3, and Cxcl9. Furthermore, gene ontology and pathway enrichment analyses revealed that microglial Nox2 plays a regulatory role in multiple pathways known to be important for MS/EAE pathogenesis, including STAT3, glutathione, leukotriene biosynthesis, IL-8, HMGB1, NRF2, systemic lupus erythematosus in B cells, and T cell exhaustion signaling. Taken together, our results provide new insights into the critical functions performed by microglial Nox2 during the EAE pathogenesis, suggesting that Nox2 inhibition may represent an important therapeutic target for MS.

Highlights

  • Multiple sclerosis (MS) is one of the major neurodegenerative diseases

  • The W and H mice showed similar time-related changes in clinical phenotype and symptoms onset beginning on 9~10 days post-injection and reached peak stage at 17 dpi, while the K mice remained almost symptomless throughout the experiment

  • Our results strongly suggest that the superoxide-producing enzyme Nox2 is essential for the activation of microglia, which is critical for their ability to cause persistent neuroinflammation

Read more

Summary

Introduction

Many drugs are available for MS therapy, but these treatments often do not effectively halt disease progression. The identification of disease-modifying drugs that can stop MS progression are urgently needed [1]. Mouse experimental autoimmune encephalomyelitis (EAE) is widely used to model human MS [2]. The key features of the mouse EAE model that somewhat recapitulate the several immunopathological and neuropathological features of human MS include inflammation, demyelination, axonal loss, and gliosis [3]. While the roles performed by immune cells related to autoimmune functions [e.g. autoreactive CD4+ T cells (TH1 and TH17 cells), CD8+ T cells, memory B cells, and myeloid cells (monocytes, dendritic cells)] are well known [4], the influence of microglia on MS/EAE remains unclear

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.